1. France Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Sanofi

Sanofi

SNYNF
SanofiUS flagOther OTC
86.61
USD
+2.64
- -
104.12BMarket Cap

Total Valuation

Sanofi carries a market capitalization of 104.12B, placing it among publicly traded companies globally. Its enterprise value stands at 112.89B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap104.12B
Enterprise Value112.89B

Share Statistics

Sanofi currently has 1.20B shares outstanding.

Shares Outstanding1.20B
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Sanofi trades at a trailing price-to-earnings ratio of 12.98.

PE Ratio12.98
PS Ratio2.07
PB RatioN/A
P/TBV Ratio24.18
P/FCF Ratio9.49
P/OCF Ratio9.49

Enterprise Valuation

On an enterprise value basis, Sanofi trades at an EV/EBITDA multiple of 12.02 and an EV/FCF ratio of 10.47. The EV/Sales ratio of 2.38 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 12.02 provides insight into valuation relative to core operating earnings.

EV / Sales2.38
EV / EBITDA12.02
EV / EBIT12.02
EV / FCF10.47

Financial Position

Sanofi maintains a current ratio of 1.01, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 27.37, indicating elevated leverage, while an interest coverage ratio of 17.73 demonstrates strong ability to service its debt obligations.

Current Ratio1.01
Quick Ratio0.20
Debt / Equity27.37
Debt / EBITDA2.13
Interest Coverage17.73

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)5.81
Return on Invested Capital (ROIC)8.26
Return on Capital Employed (ROCE)38.21
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover0.59

Taxes

Over the trailing twelve months, Sanofi has paid 982.00M in income taxes, reflecting an effective tax rate of 16.31.

Income Tax982.00M
Effective Tax Rate16.31

Stock Price Statistics

Sanofi's stock has declined approximately -10.47137% over the past 52 weeks. The 50-day moving average sits at 90.53, while the 200-day moving average is 94.75.

Beta (5Y)N/A
52-Week Price Change-10.47137%
50-Day Moving Average90.53
200-Day Moving Average94.75
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Sanofi generated 47.35B in revenue and converted that into 7.56B in net income, yielding earnings per share of 4.02. EBITDA reached 9.40B, while operating income came in at 9.40B.

Revenue47.35B
Gross Profit34.06B
Operating Income9.40B
Pretax Income6.02B
Net Income7.56B
EBITDA9.40B
EBIT9.40B
Earnings Per Share (EPS)4.02

Balance Sheet

Sanofi holds 5.54B in cash and equivalents against 20.02B in total debt, resulting in a net debt position of 12.68B.

Cash & Cash Equivalents5.54B
Total Debt20.02B
Net Debt12.68B
Equity (Book Value)N/A
Book Value Per ShareN/A
Working Capital156.00M

Cash Flow

Sanofi produced 10.34B in operating cash flow over the past twelve months.

Operating Cash Flow10.34B
Capital ExpendituresN/A
Free Cash Flow10.34B
FCF Per Share8.56

Margins

Sanofi operates with a gross margin of 71.92, reflecting its pricing power and cost economics. The operating margin of 19.84 and net profit margin of 15.95 provide insight into operational efficiency.

Gross Margin71.92
Operating Margin19.84
Pretax Margin12.71
Profit Margin15.95
EBITDA Margin19.84

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield9.32
FCF Yield10.54

Stock Splits

Sanofi's most recent stock split took place on May 6, 2022 with a 1000:1005 split ratio.

Last Split Date5/6/2022
Split Ratio1000:1005

Scores

Sanofi posts an Altman Z-Score of 2.41, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.41